John Townsend, MD
Neurology · Newark, DENPI 1982656245
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations.
Across 52 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$172
- Sunovion Pharmaceuticals Inc.$113
- AstraZeneca$103
- Biogen$66
- Teva Pharmaceuticals USA, Inc.$61
- Shire North American Group Inc$58
- plus $310 from 11 others
What the payments were for
- Food & beverage$883100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 8 | $172 |
| Sunovion Pharmaceuticals Inc. | 8 | $113 |
| AstraZeneca | 5 | $103 |
| Biogen | 4 | $66 |
| Teva Pharmaceuticals USA, Inc. | 4 | $61 |
| Shire North American Group Inc | 4 | $58 |
| Lilly USA, LLC | 3 | $52 |
| Sanofi | 3 | $50 |
| EMD Serono, Inc. | 2 | $40 |
| Arbor Pharmaceuticals, Inc. | 3 | $38 |
| Ironshore Pharmaceuticals Inc. | 2 | $30 |
| Tanabe Pharma America, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Harmony Biosciences LLC | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $15 |
| GRT US Holding, Inc. | 1 | $14 |
| AbbVie | 1 | $13 |
How this compares
$883 in reported general payments places this provider in the 60th percentile of 61 neurology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GocovriAmantadine Hcl | 14 | $22,829 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 100 | $4,507 |
| Methylphenidate ErMethylphenidate Hcl | 26 | $2,082 |
| Propranolol Hcl ErPropranolol Hcl | 38 | $1,994 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 47 | $1,987 |
| Gabapentin | 86 | $1,627 |
| Pyridostigmine Bromide | 21 | $1,397 |
| Donepezil Hcl | 83 | $1,272 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 20 | $1,209 |
| Modafinil | 17 | $1,054 |
| Levetiracetam | 24 | $961 |
| Ropinirole Hcl | 34 | $853 |
| Nortriptyline Hcl | 47 | $847 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 29 | $832 |
| Duloxetine Hcl | 16 | $769 |
Paid to pharmacies, not to this prescriber.
Other neurology in Newark
- Justin MartelloNewark$485K
- Jason SilversteenNewark$202K
- Etsegenet TizazuNewark$15K
- William SommersNewark$14K
- Lee DresserNewark$12K
- John PollardNewark$7K
- Shilpa KautaNewark$7K
- Brian OommenNewark$2K
- Huijun WangNewark$1K
- Muhammad AfzalNewark$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.